OM137

• 产品号: O8140
• CAS号: 292170-13-9
• 分子式: C13H14N4O3S
• 分子量: 306.34026
• 纯 度: ≥95% (NMR)

产品别名

• 标题: OM137
• IUPAC标准名: 2-amino-N'-[(4-hydroxy-3-methoxyphenyl)methylidene]-4-methyl-1,3-thiazole-5-carbohydrazide
• IUPAC传统名: 2-amino-N'-[(4-hydroxy-3-methoxyphenyl)methylidene]-4-methyl-1,3-thiazole-5-carbohydrazide
• 别名: 2-Amino-N′-(4-hydroxy-3-methoxybenzylidene)-4-methyl-1,3-thiazole-5-carbohydrazide; 5-Thiazolecarboxylic acid, 2-amino-4-methyl-, 2-[(4-hydroxy-3-methoxyphenyl)methylene]hydrazide

产品登记号

• MDL号: MFCD02086738
• CAS号: 292170-13-9

产品性质

• Empirical Formula (Hill Notation): C13H14N4O3S
• 纯度: ≥95% (NMR)
• 外观: powder
• 溶解度: DMSO: >10 mg/mL
• GHS警示词: Warning
• GHS危险声明: H302-H315-H319-H335
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• GHS警示性声明: P261-P305 + P351 + P338
• 危险公开号: 22-36/37/38
• 安全公开号: 26
• 保存温度: room temp
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Biochem/physiol Actions
OM137 is an inhibitor of aurora kinases; inhibitor of spindle checkpoint. OM137 is an aminothiazole derivative, which functions to override the spindle checkpoint primarily through inhibition of the Aurora kinases (mitotic kinases). OM137 is a more potent inhibitor of Aurora B compared with Aurora A in vitro, consistent with the effects of OM137 on checkpoint function in living cells. The compound has some CDK1 inhibitory activity, but is likely that the major mode by which OM137 drives mitotic exit of cells arrested in M phase via the spindle checkpoint is through its inhibitory activity against Aurora B kinase. The compound is less potent than N-[4-[(6,7-Dimethoxy-4-quinazolinyl)amino]phenyl]benzamide hydrochloride (Sigma Cat. D6068), which is more suited for in vitro testing due to low solubility and high serum binding. OM137 is less potent than selective Aurora A inhibitor, cyclopropanecarboxylic acid {3-[4-(3-trifluoromethyl-phenylamino)-pyrimidin-2-ylamino]-phenyl}-amide (Sigma Cat. C2368).

详细说明 (简体中文)

Biochem/physiol Actions
OM137 is an inhibitor of aurora kinases; inhibitor of spindle checkpoint. OM137 is an aminothiazole derivative, which functions to override the spindle checkpoint primarily through inhibition of the Aurora kinases (mitotic kinases). OM137 is a more potent inhibitor of Aurora B compared with Aurora A in vitro, consistent with the effects of OM137 on checkpoint function in living cells. The compound has some CDK1 inhibitory activity, but is likely that the major mode by which OM137 drives mitotic exit of cells arrested in M phase via the spindle checkpoint is through its inhibitory activity against Aurora B kinase. The compound is less potent than N-[4-[(6,7-Dimethoxy-4-quinazolinyl)amino]phenyl]benzamide hydrochloride (Sigma Cat. D6068), which is more suited for in vitro testing due to low solubility and high serum binding. OM137 is less potent than selective Aurora A inhibitor, cyclopropanecarboxylic acid {3-[4-(3-trifluoromethyl-phenylamino)-pyrimidin-2-ylamino]-phenyl}-amide (Sigma Cat. C2368).